Fig. 3.

Cisplatin triggers immunogenic cell death and antigen releasing in vitro or vivo. A Mouse prostate cancer cells were treated with cisplatin for 24 h followed by the assessment of Annexin V/PI staining (n = 3). B Elisa assay quantification of proteins (IFNα or HMGB1) levels in tumor homogenate following cisplatin intumoral administration for 72 h (n = 3). C ELISA dynamic detection of antigen protein STEAP1 levels in serum of tumor-bearing mice at 24,48, 72,96 h post-cisplatin administration (n = 3, *P < 0.05, **P < 0.01, ***P < 0.001)